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Abstract
Background: HIV and AIDS are significant and growing public health concerns in southern Africa.
The majority of countries in the region have national adult HIV prevalence estimates exceeding 10
percent. The increasing availability of highly active antiretroviral therapy (HAART) has potential to
mitigate the situation. There is however concern that women may experience more barriers in
accessing treatment programs than men.
Methods: A systematic review of the literature was carried out to describe the gender distribution
of patients accessing highly active antiretroviral therapy (HAART) in Southern Africa. Data on
number of patients on treatment, their mean or median age and gender were obtained and
compared across studies and reports.
Results: The median or mean age of patients in the studies ranged from 33 to 39 years. While
female to male HIV infection prevalence ratios in the southern African countries ranged from 1.2:1
to 1.6:1, female to male ratios on HAART ranged from 0.8: 1 to 2.3: 1. The majority of the reports
had female: male ratio in treatment exceeding 1.6. Overall, there were more females on HAART
than there were males and this was not solely explained by the higher HIV prevalence among
females compared to males.
Conclusion: In most Southern African countries, proportionally more females are on HIV
antiretroviral treatment than men, even when the higher HIV infection prevalence in females is
accounted for. There is need to identify the factors that are facilitating women's accessibility to HIV
treatment. As more patients access HAART in the region, it will be important to continue assessing
the gender distribution of patients on HAART.
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There is increasing global interest to ensure that HIV
infected persons have access to antiretroviral therapy. In
the developed world, mortality from AIDS has signifi-
cantly reduced, in part due to wide availability and acces-
sibility to highly active antiretroviral therapy (HAART). In
resource-limited countries however, although there has
been steady progress in increasing accessibility to antiret-
roviral therapy (ART), most patients have no access to this
life saving intervention [1]. Natrass suggests that the poor
and vulnerable segments of society are likely to miss out
from accessing HAART. In many societies, women are
likely to be poor and socially vulnerable.
When patients in resource limited settings access HAART,
treatment adherence has been reported to be comparable
to industrialized countries [2]. The benefits of treatment
have also been suggested to contribute to overall HIV pre-
vention [3]. However the benefits of HAART in resource-
limited countries may be restricted as even when patients
receive HAART, they often do so very late in the disease
[4].
Southern Africa is the region of the world that has been
hardest hit by the HIV pandemic. For instance, Malawi's
adult (15–49 years) HIV prevalence was estimated at
14.4% in the Malawi Demographic and Health Survey in
2004 [5]. Zambia's HIV prevalence in the 15–49 years age
group was 15.6% in the Zambia Demographic and Health
Survey 2000–01 [6]. In Namibia, 10% of the 15 to 49
years old were HIV infected in 2005 [7]. While most of the
countries in the region have very high HIV prevalence esti-
mates exceeding 10%, the Democratic Republic of Congo
(DRC) has 4.5% of its population infected [8]. These fig-
ures from the DRC are likely to be unreliable as health
infrastructure in the country outside the capital city is
almost non-existent due to several years of civil war. The-
obald et al have expressed concern that HAART scaling-up
may "continue to serve the needs of dominant powerful
groups in society and undermine a true public health
approach" [9]. Women in most societies contribute the
largest group of socially vulnerable members. There is
therefore legitimate concern that women may not be
accessing HAART programs as well as men due to personal
and societal barriers. Krawczyk et al, have studied the bar-
riers in accessing HIV care in the southern states of the
United States [10]. Gender, sexual behaviors, stigma, lack
of health insurance and poverty, and social support all
had a bearing in influencing decisions to access care. In
general, non-whites, women, and the poor are unlikely to
access care, and when they do, it was usually late. In other
studies however, men have been reported to seek care late
at times when symptoms are far advanced [11].
The situation in southern Africa though has not been well
described probably because comprehensive HIV care
which incorporates HAART is a relatively new phenome-
non. With the scaling up of HAART programs and com-
prehensive care going on in the continent, there is need to
describe the distribution of patients obtaining HAART in
terms of gender and age. Some of the questions that need
to be addressed are: Is there gender balance in the distri-
bution of patients obtaining HAART? What age groups are
more likely to access HAART? Answers to these questions
may help to guide researchers and policy makers to iden-
tify operational gaps, and suggest interventions that may
improve accessibility of patients to health services. We
aimed to obtain answers to these questions by conducting
a systematic review of published literature following the
suggestions of the Meta-analysis of Observations Studies
in Epidemiology (MOOSE) Group published by Stroup et
al [12].
Methods
Search Strategy and Selection Criteria
We searched for peer-reviewed articles and conference
abstracts published in English language that reported on
gender distribution of adult patients obtaining highly
active antiretroviral therapy (HAART) in treatment pro-
grams in southern Africa. Different combinations of the
following keywords: "antiretroviral", "anti-retroviral",
"highly active antiretroviral therapy", "HAART", "AIDS
treatment" and "HIV treatment" and a combination of
these terms to each of the southern African countries were
used. For the purposes of this paper, southern Africa was
defined as all the 14 countries that make up the Southern
African Development Community (SADC). These coun-
tries are: Angola, Botswana, Democratic Republic of
Congo (DRC), Lesotho, Madagascar, Malawi, Mauritius,
Mozambique, Namibia, Seychelles, South Africa, Swazi-
land, Tanzania, Zambia and Zimbabwe.
Electronic searches of MEDLINE, PsycINFO, African Jour-
nals Online (AJOL), Ingenta and Ovid electronic data-
bases were done for reports published from 2000 to
August 15, 2006. We also searched electronically for con-
ference abstracts on Gateway [13] and manually for rele-
vant HIV, Virology and retroviral conference abstracts.
HIV prevention, treatment and support program reports
from the Ministries of Health were obtained and reviewed
manually. References from articles retrieved were exam-
ined to determine if they would lead us to other papers
that had the information we were seeking.
We included a study or program document for review if it
reported on the following within a treatment program:
the gender distribution of patients on HAART, mean or
median age of patients and time period of accumulation
of patients on treatment of not less than 6 month. JournalPage 2 of 8
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program treatment and not randomized clinical trials or
any aggregation of patients whose composition was deter-
mined by the authors or researchers i.e. we aimed to cap-
ture the natural flow of patients accessing HAART.
The following information was extracted from the studies
and relevant program documents: authors, setting of
study, duration of accumulation of cases included in the
study, male and female distribution of cases, whether pro-
gram required patients to pay for medication or medica-
tions were provided for free and mean or median age of
patients on treatment.
We also contacted by email, 20 corresponding authors of
the articles that we retrieved and HIV and AIDS national
program officials asking them whether they were aware of
any other reports on HAART provision in the southern
African countries they were working.
In order to determine whether there was gender balance
or imbalance among patients accessing HAART care, we
compared the estimated gender ratio of HIV infection
prevalence in a specific country to the gender ratio on
treatment. We used the UNAIDS 2005 data of national
HIV prevalence estimates [14]. This ratio was extrapolated
and interpreted in such a way that we suggested that the
same gender ratios would be expected to be obtained for
patients accessing care. If the gender ratio between
expected numbers of HIV infected and those receiving
HAART care did not match, this was interpreted as evi-
dence of inequity.
We did not attempt to assess whether any patients within
a study area were included in only one study or report. As
the purpose of the study was to assess the gender distribu-
tion of patients, patient serially recorded still served our
purpose which was to estimate what was the gender distri-
bution of patients at any particular time data were
reported (multiple cross sectional studies).
Results
We identified 21 reports that were eligible to be included
in the review [15-35]. We obtained only 6 responses from
the 20 emails that were sent to persons we had contacted.
Table 1 reports on number of HIV infected adults distrib-
uted by gender and the gender ratios of estimated infec-
tions in southern African countries.
Table 1 shows that South Africa has the largest number of
HIV infected adults in Southern Africa. The gender ratios
(female to male) of infected adults range from 0.4 in
Madagascar to 1.6 in Zimbabwe. Four countries have 1.2
gender ratio, 6 have 1.3 and one each have 1.4 and 1.6.
Table 2 below reports the number of patients on treat-
ment and their demographic characteristics, including
gender. Gender ratios on treatment have been computed
and these are also presented in the table.
The reported median or mean age of patients reported
ranged from 33 to 39 years. In 3 studies, there was a male
predominance in treatment programs, one each from
Malawi, Swaziland and Zambia. The majority of the stud-
ies however reported a > 1.0 female to male ratio. Ten
studies reported a female to male ratio exceeding 1.6 (the
highest ratio for HIV infected females to infected males
reported in Table 1). All reports of programs enrolling > =
1000 patients reported female predominance.
Discussion
Our study found that published data do not suggest that
women are at a disadvantage when compared to men
when accessing HAART in southern Africa. The predomi-
nance of women in HAART programs to an extent reflects
the gender proportions of the adult population infected
with HIV in southern Africa. For instance, the Zambia
Table 1: Adult Male versus Female HIV prevalence distribution in Southern Africa, 2005 [14]
Country Female Prevalence Male Prevalence Female: Male Ratio
Angola 160,000 120,000 1.3
Botswana 140,000 120,000 1.2
DRC 490,000 400,000 1.2
Lesotho 140,000 110,000 1.3
Madagascar 13,000 36,000 0.4
Malawi 480,000 370,000 1.3
Mozambique 920,000 680,000 1.4
Namibia 120,000 90,000 2.1
South Africa 2,900,000 2,400,000 1.2
Swaziland 120,000 90,000 1.3
United Republic of Tanzania 680,000 550,000 1.3
Zambia 540,000 460,000 1.2
Zimbabwe 930,000 570,000 1.6Page 3 of 8
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Table 2: Gender and Age Distribution of Patients on HAART in Selected Southern Africa
Country Authors Period Study Site Number of patients on ARVs Males (%) Females (%) Female :ratio Mean/Median Age in Yrs
Botswana Ndwapi et al [15] 2002 Gaberone 306 135 (44%) 171 (56%) 1.3 36.8
Wester et al [16] 1999–2004 Gaberone 153 62 (41%) 91 (59%) 1.5 36
Bisson et al [17] 1999–2004 Gaberone 305 129 (42%) 175 (58%) 1.4 37
Malawi Hosseinipour et al [18] 2003 Lilongwe 141 67 (48%) 74 (52%) 1.1 38.5
van Oosterhaut et al [19] 2003 Blantyre 176 80 (40%) 96 (55) 1.2 39
Zachariah et al [20] 2003–05 Thyolo 1634 572 (35%) 1062 (65) 1.9 33
Ferradini et al [21] 2001–03 Chiradzulu 1308 481 (36%) 827 (64%) 1.7 34.9
Hosseinipour et al [22] 2001–03 Lilongwe 625 376 (51.5%) 354 (48.5) 0.9 38
Bonnet et al [23] 2001–03 Chiradzulu 1033 367 (35.5%) 666 (64.5%) 1.8 35
Libamba et al [24] 2001–05 Malawi 13183 5274 (40%) 7909 (60%) 1.5 Not specified
Phiri and Boxshall [25] 2001–05 Malawi 35841 14819 (35.6%) 23021 (64.4%) 1.6 33
Malawi MoH [26] 2001–06 National 46,702 18213 (39%) 28,488(61%) 1.6 Not specified
Mozambique Palombi et al [27] 2002–3 Machava 802 292 (36.4%) 510 (63.6%) 1.7 Not specified
South Africa Stewart & oveday [28] 1999–04 National 8149 2824 (35%) 5325 (65%) 1.9 Not specified
Coetzee et al [29] 2001–2 Khayelitsha 287 86 (30%) 201 (70%) 2.3 Not specified
Hassan and Bosch [30] 2001–04 Eastern Cape 4147 1499 (36.1%) 2648 (63.9%) 1.8 Not specified
Hassan and Bosch [30] 2001–05 Northern Cape 3156 1005 (31.8%) 2151 (68.2%) 1.5 Not specified
Swaziland Ericsdotter [31] 2003–05 Mbabane 4800 2688 (56%) 2112 (44%) 0.8 Not specified
Tanzania TACAIDS [32] 2004–6 National 12000 < 50% > 50% > 1 Not specified
Zambia Stringer et al [33] 2004–05 Lusaka 21755 8109 (37%) 13646 (63%) 1.7 35
Sinkala et al [34] 2004–05 Lusaka 22121 11691 (51.7%) 10691 (48.3%) 1.1 35
Ministry of Health [35] 2002–05 National 3982 1638 (41%) 2344 (59%) 1.4 not specified
BMC Public Health 2007, 7:63 http://www.biomedcentral.com/1471-2458/7/63Demographic and Health Survey 2000–01 [6] national
HIV prevalence for persons aged 15 yrs to 49 years was for
17.8% for females and 12.9% for males. As a proportion
of all adults accessing HAART, women are in the majority
outnumbering men.
Several authors have reported that women access HIV care
earlier than men in the United States [36-38]. Others
authors though have reported opposite findings [39]. The
improvements in access of HIV testing among women
attending antenatal care (ANC) has been reported as an
important entry point for these women into HIV care and
the support pipeline [40]. In southern Africa, there is also
a drive to encourage women attending ANC to be tested
for HIV in an effort to reduce vertical HIV transmission.
Such drives could contribute to the higher access of
women to HIV care services. The extent however to which
HIV antenatal services have contributed to overall HAART
programs need to be evaluated.
In some HIV testing programs outside of antenatal care,
there has been a predominance of females over men in
many settings [41]. In 2004 in Malawi, out of 283,467
persons tested for HIV across the country, 15% were
women accessing antenatal care. However, in free stand-
ing testing services provided by the Malawi AIDS Coun-
seling and testing Organization (MACRO), of the 33,441
people tested, only 31% were female [42]. This pattern of
low female representation was observed at three sites.
Whether women were under-represented because they
had other access through antenatal care was not
described. It has to be recognized also that although there
may be more males accessing HIV testing, proportionally
more women are likely to test positive than males in
southern Africa. Women are the primary care givers in
homes in virtually all countries in southern Africa and are
likely to present to health facilities with sick family mem-
bers. They also generally have greater interaction with
health care services as they obtain maternity and family
planning related care. Women's familiarity with health
services may be working in their favour by facilitating
their access to health services for HAART.
In many sub-Saharan countries, it is believed that women
are mainly infected with HIV by their own spouses
[43,44]. It is therefore possible that men may be reluctant
to acknowledge that they may be infected compared to
women who may be forthright in accessing care believing,
and little stigmatized as HIV is perceived to have been
acquired from a spouse. Men on the other hand may fear
that they may be perceived to have acquired infection out-
side of marriage. Krawczyk et al reported that anticipated
stigma was associated with delay in seeking HIV care in
the United States [10].
Bachmann has reported that late initiation of HIV treat-
ment was less cost-effective than early initiation of ther-
apy in southern Africa [45]. It is therefore pertinent that
an assessment is made to determine at which points in the
care continuum delays occur in accessing care. Delays can
occur due to patient factors and intrinsic health system
factors [46].
Badri et al have suggested that for resource-limited set-
tings, prioritizing symptomatically very sick patients for
HAART is likely to be the most rational way of scaling-up
HAART programs [47]. Palombi et al however argued that
"this minimalistic approach" is likely to put many people
in harms way unnecessarily by delaying therapy to a point
where it may not be as effective anymore due to unre-
deemable immune compromise [48]. The harm that may
result from delay in initiating therapy has probably been
shown in Malawi by Zachariah et al [49] where advanced
HIV disease is shown to significantly contribute to mortal-
ity among patients on HAART. Hosseinipour et al [50]
have also demonstrated a high mortality of patients
within the first few weeks into entry to HAART programs.
If males are presenting late into treatment programs they
are likely to suffer significant mortality and therefore limit
the benefits of HAART programs. There is need to assess
whether males have worse mortality while on HAART
compared to females. A study by Mshana et al reported
that barriers in accessing HAART included difficulties in
identifying a treatment buddy, transport costs to treat-
ment centers, fear of disclosure of HIV status and percep-
tion that hospitals were unfriendly and confusing [51].
The treatment "buddy approach" is aimed to enhance
adherence to therapy as patients have an identified treat-
ment support person. However, as the requirement to
identify a treatment buddy seems widespread in southern
Africa [51],[52] there is need to assess its pros and cons.
For instance, could it be that men have trouble identifying
treatment buddies and so may be under-represented in
treatment programs? Any suggestion to change the policy
should also consider the potential loss in patient treat-
ment adherence that may occur in the absence of a treat-
ment buddy, who is currently perceived as key in
supporting patients.
HIV prevalence is highest in the 30–34 years group at
19.2% and 29.4% respectively. Of particular note also is
the fact that the mean or median ages for patients on
HAART treatment ranged from 33 and 38 years. This sug-
gests that the groups with highest likelihood of symptoms
i.e. approximately 10 years following infection are also
being fairly represented in treatment programs. It is also
important to note that most recently infected person do
not become clinically eligible for HAART under the cur-
rent guidelines in operation in most of the countries. Peo-
ple who are starting treatment may have acquiredPage 5 of 8
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for HAART due to waning immunity. As this study was
restricted to adult treatment programs, the situation in
children may be different.
With reference to Table 2, it is interesting to note that in
general the gender distribution seem to be maintained
across programs despite of differences as to whether
patients were required to pay for medications or not.
It is interesting to note that the study by Hosseinipour et
al [18] reported on a period when a fee-paying HAART
treatment program was running in Lilongwe i.e. before
free treatment was started. During this period, there were
slightly more males (51.5%) than females (48.5%) and
patient drop out was at 35.5%. In Zambia high drop-out
rate were also observed prior to 2004 when most of the
patients were obtaining HAART on fee-paying basis [28].
At this time, there were 52.1% females versus 47.9%
males on HAART. Subsequent to the introduction of
national free HAART services, there are more women than
males on treatment. However, in general there was still
female gender predominance even in paying treatment
programs.
There are several limitations of this review. Firstly data
were mostly obtained from peer reviewed journals
indexed in the databases that we reviewed. Treatment pro-
grams that did not publish reports were therefore missed.
We however complemented the lack of peer-reviewed
publications with abstracts from conferences. Again this
source of data may be selective. If HAART treatment that
did not publish their experiences have different gender
distribution from those that published, then our conclu-
sions may have to be revised. We however do not believe
that the non-published experiences were overall systemat-
ically different from the reports reviewed in our study. The
strength of our study also comes from the fact that we
have presented data obtained at different time periods
within the same country but still consistently showed that
the gender distribution was in favour of females. This
probably offers strongest evidence that the gender pattern
is unlikely to be spurious or fluctuating but rather it is a
stable phenomenon. The report from Tanzania [32] was
less informative as the actual numbers were not reported.
The percentages of patients on HAART were however pro-
vided.
As our search was limited to publications in English, it
was possible that we missed some relevant articles pub-
lished in French (Democratic Republic of Congo) and
Portuguese (Angola and Mozambique). We were however
able to find articles in English from Mozambique, a Por-
tuguese-speaking country, and these were included in the
review. There was also likely to be overlapping of patients
cohorts among the reports. For instance, in any country
where both national treatment figures and localized
patient numbers where obtained, many of the patients at
the local setting would also be counted within the
national figures. We do believe that such double counting
in fact emphasizes the point that even when both larger
and smaller patient cohorts were assessed, the gender dis-
tributions were maintained.
Conclusion
The available published data suggest that females may not
be disadvantaged in accessing highly active anti-retroviral
therapy in Africa. From the limited available reports how-
ever, there was either gender balance within treatment
programs or predominance of females within treatment
programs. There is need to identify facilitating factors that
enhance high uptake of women on HAART programs in
order to sustain the current successes. There is also need to
identify barriers against accessing care by males. This will
ensure that both genders have fair access to treatment pro-
grams.
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